Ena Respiratory is developing a novel class of synthetic, topically delivered innate immunomodulators that have the capability to prime the immune system in the respiratory tract and prevent the complications associated with respiratory viral infections. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed.